NVO
Novo Nordisk A/S
NVO trails on the overall score without a compensating advantage in the available component scores.
PNTG
The Pennant Group, Inc.
PNTG has the edge over NVO overall, supported by stronger valuation and stronger fundamentals.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
PNTG Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Stable | |
| Stable |
PNTG's revenue and profitability are currently healthy, and its cash flow and balance sheet are stable.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over PNTG in the historical PE scenario, which offers more potential upside but is not a forecast.
PNTG PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 24x | $35.91 | — |
| Cheap | 35x | $35.37 | -1.5% |
| Current | 36x | $35.91 | — |
| Fair | 46x | $45.65 | +27% |
| Expensive | 87x | $86.68 | +141% |
Historical ranges are pointers, not guarantees.
PNTG's PE is in its cheap range at 36x. If earnings grow as analysts expect, today's price would be 24x next year's earnings.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
PNTG Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| High |
PNTG has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO's earnings per share have climbed steadily: $3.89 over the past year, up 4.9% from the year before, and higher year over year every quarter since late 2020.
PNTG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.52 | +52% |
| Q3 2026 | $1.00 | +33% |
| Q2 2026 | $0.91 | +17% |
| Q1 2026 | $0.86 | +13% |
| Q4 2025 | $0.84 | +20% |
| Q3 2025 | $0.75 | +10% |
| Q2 2025 | $0.78 | +24% |
| Q1 2025 | $0.76 | +41% |
| Q4 2024 | $0.70 | +59% |
PNTG has the edge over NVO on earnings, with stronger typical year-over-year growth.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over PNTG on profitability, with a higher operating margin.
PNTG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $302.3M | +32% |
| Q2 2026 | $298M | +36% |
| Q1 2026 | $285.4M | +36% |
| Q4 2025 | $289.3M | +53% |
| Q3 2025 | $229M | +27% |
| Q2 2025 | $219.5M | +30% |
| Q1 2025 | $209.8M | +34% |
| Q4 2024 | $188.9M | +29% |
PNTG has the edge over NVO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.5% | +1 points |
| Q2 2026 | 5.8% | +0.5 points |
| Q1 2026 | 6.1% | 0 points |
| Q4 2025 | 6% | +1.2 points |
| Q3 2025 | 4.5% | -1.5 points |
| Q2 2025 | 5.3% | -0.4 points |
| Q1 2025 | 6% | +0.6 points |
| Q4 2024 | 4.9% | -0.3 points |
PNTG's operating margin was 5.5% last quarter, up 1 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
PNTG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $10.1M | -3.2% |
| Q2 2026 | $15.5M | -51% |
| Q1 2026 | -$8.7M | +$14.5M |
| Q4 2025 | $17.4M | +0.9% |
| Q3 2025 | $10.5M | +54% |
| Q2 2025 | $31.6M | +256% |
| Q1 2025 | -$23.2M | -$20.6M |
| Q4 2024 | $17.2M | +511% |
PNTG generated $34M in free cash flow over the past year, down 4.9% from the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over PNTG on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
PNTG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +427K shares |
| 1 year | +3.2% | +1.1M shares |
| 3 years | +20% | +6.2M shares |
| 5 years | +19% | +5.8M shares |
| Available history | +23% | +6.8M shares |
PNTG has 36M diluted shares, up 3.2% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2021 | — |
| Q3 2021 | — |
| Q4 2020 | — |
| Q3 2020 | $8,000 |
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO has the edge over PNTG on leverage, with a lower net debt burden relative to earnings.
PNTG Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.2x | Moderate |
| Q2 2026 | 2.5x | Moderate |
| Q1 2026 | 2.4x | Moderate |
| Q4 2025 | 2.5x | Moderate |
| Q3 2025 | 0.5x | Very low |
| Q2 2025 | 0.4x | Very low |
| Q1 2025 | 1.0x | Very low |
| Q4 2024 | -0.6x | Net Cash |
PNTG's net debt is about 2.2 years of its operating earnings (EBITDA), up from less than a year a year ago.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
PNTG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.9 | Neutral |
| Stochastic | 27.8 | Neutral |
PNTG's weekly RSI is 45 (neutral) and its Stochastic is 28 (neutral).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over PNTG on valuation relative to its sector.
PNTG PE vs Healthcare Sector
| Metric | PNTG | Sector median | Relative |
|---|---|---|---|
| PE | 36x | 26x | 39% above |
| PE % | 18 | 29 | 11 pts below |
PNTG is trading at 36x earnings, a 39% premium to the Healthcare sector's median of 26x.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
PNTG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.7 | 9.5% below |
| 20 week MA | $39.6 | 9.2% below |
| 50 week MA | $34.7 | 3.6% above |
| 100 week MA | $30.2 | 19% above |
| 200 week MA | $24.5 | 46% above |
PNTG has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
PNTG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $32.2 | $61.0 | +90% |
| 2021 | $61.0 | $21.9 | -64% |
| 2022 | $21.9 | $9.95 | -55% |
| 2023 | $9.95 | $13.9 | +40% |
| 2024 | $13.9 | $26.6 | +91% |
| 2025 | $26.6 | $29.1 | +9.1% |
| 2026 YTD | $29.1 | $35.9 | +24% |
PNTG has the edge over NVO on returns for 2026, with the stronger performance.